The global blood screening market was valued at USD 2.31 billion in 2018 and is expected to reach USD 6.63 billion by 2032, growing at a compound annual rate of 7.9% over the forecast period. In 2018, North America held the largest share of the market at 41.86%.
The global blood screening market has experienced steady growth and is projected to expand significantly over the coming years. Rising demand for safe blood transfusions, increasing prevalence of infectious diseases, and technological advancements in screening methods are key factors driving this growth. North America currently leads the market due to strong healthcare infrastructure and early adoption of advanced technologies, while other regions are rapidly emerging as important contributors.
Learn more here:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation
By Product
Reagents and Kits: Widely used for screening of infectious markers and dominating due to their recurring use.
Instruments: Includes automated analyzers and devices for nucleic acid testing, immunoassays, and rapid testing platforms.
Software and Services: Growing in importance as data management and automation become critical in blood banks and laboratories.
By Technology
Nucleic Acid Testing (NAT): Highly sensitive technology increasingly adopted to detect viral infections at early stages.
Enzyme-Linked Immunosorbent Assay (ELISA): Extensively used and evolving with chemiluminescent and advanced formats.
Rapid Tests: Used for quick screening in resource-limited or emergency settings.
Western Blotting and Next-Generation Sequencing: Applied for confirmatory and advanced diagnostic purposes.
By Application
Infectious Disease Screening: Focused on detection of HIV, hepatitis, syphilis, malaria, and other transfusion-transmissible infections.
Blood Group Typing: Essential for ensuring compatibility in transfusions and transplantation.
By End User
Blood Banks: Major end users performing high volumes of routine screening.
Hospitals and Clinics: Conduct testing for transfusions and patient care.
Clinical Laboratories: Provide specialized testing services, often outsourcing from smaller facilities.
list of key companies profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Market Growth Drivers
The market is driven by increasing demand for safe blood transfusions, rising prevalence of chronic and infectious diseases, and growing adoption of advanced molecular technologies. Awareness initiatives by governments and organizations are encouraging stringent safety protocols. Automation and digitalization are enhancing efficiency and accuracy in testing. In addition, the growing need for early disease detection supports the integration of blood screening in preventive healthcare.
Market Restraining Factors
High costs associated with advanced technologies limit adoption in low-resource settings. Strict regulatory requirements can delay product launches and increase compliance costs. Shortage of trained laboratory professionals poses challenges for widespread implementation. Limited infrastructure in developing regions restricts accessibility to advanced screening methods. Furthermore, alternative diagnostic approaches and limited reimbursement policies can restrain growth.
Regional Analysis
North America: Leads the market due to advanced healthcare infrastructure, strong regulatory frameworks, and early adoption of innovative technologies.
Europe: Maintains a significant share supported by strict safety standards, government initiatives, and established blood banking networks.
Asia–Pacific: Expected to grow rapidly due to rising population, increasing prevalence of infectious diseases, expanding healthcare infrastructure, and government investment in blood safety programs.
Latin America: Witnessing steady growth as healthcare systems improve and awareness about blood safety increases.
Middle East & Africa: Showing gradual progress with growing demand for transfusions and international collaborations to strengthen blood screening facilities.